Co-inhibitory CTLA-4 competes with co-stimulatory CD28 to bind to CD80 or CD86 on the surface of APCs to alleviate the anti-tumor immunity of tumor infiltrated T lymphocytes (TILs), such as CD4+T, CD8+T cells and regulatory T cells (Tregs). The gene discussed is CD28; the disease is neoplasm.